|
COPYRIGHT 2005 Asia Pulse Pty Ltd
(Full text of statement. Contact details below.)
BRASILIA, Brazil, June 24 /PRNewswire-AsiaNet/ --
The Government declares anti-retroviral Kaletra to be of public interest and will produce it in Brazil
The Ministry of Health of Brazil has declared the anti-retroviral drug Kaletra (Lopinavir/ritonavir), manufactured by Abbott Laboratories, to be of public interest. As such, the Brazilian government will adopt obligatory licensing of the medication, in the case that the manufacturer does not provide the necessary requirements to guarantee the sustainability of the National STD/AIDS Program. An official notice sent this Friday to the Laboratory opens the door for the company to express its opinion on whether it will address this situation in the public's interest.
(Photo: http://www.newscom.com/cgi-bin/prnh/20050623/SPF001 )
The Laboratory will have 10 days from receipt of this notice to inform the Brazilian Ministry of Health that it is prepared to reduce the sales price of Kaletra to national production levels. Its agreement will prevent the adoption of obligatory licensing.
With the licensing, the government will be able to allow Farmanguinhos Laboratory, from Fiocruz, to produce the medicine for exclusive public, and not commercial, use. This measure is necessary to maintain the sustainability and the quality of the National STD/AIDS Program, which is responsible for guaranteeing...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
